{"id":575,"date":"2005-06-01T12:06:00","date_gmt":"2005-06-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/infliximab-toedliche-exazerbation-von-fibrosierender-alveolitis-bei-rheumatoider-arthritis-drei-faelle"},"modified":"2005-06-01T12:06:00","modified_gmt":"2005-06-01T10:06:00","slug":"infliximab-toedliche-exazerbation-von-fibrosierender-alveolitis-bei-rheumatoider-arthritis-drei-faelle","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/infliximab-toedliche-exazerbation-von-fibrosierender-alveolitis-bei-rheumatoider-arthritis-drei-faelle","title":{"rendered":"Infliximab: T\u00f6dliche Exazerbation von Fibrosierender Alveolitis bei Rheumatoider Arthritis: Drei F\u00e4lle"},"content":{"rendered":"<p>Antik\u00f6rper gegen Tumor-Nekrose-Faktor alpha (TNF alpha) werden zunehmend bei schwer verlaufenden chronisch-entz\u00fcndlichen Erkrankungen angewendet (1). A.J.K. Ostor et al. aus England (2) berichten \u00fcber Verl\u00e4ufe bei drei Patienten mit Rheumatoider Arthritis (RA), deren pr\u00e4existente pulmonale Manifestation (Fibrosierende Alveolitis) nach Einsatz von Infliximab (Remicade\u00ae) mit Todesfolge exazerbierte. Die Patienten (zwei Frauen, ein Mann) waren zwischen 67 [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antik\u00f6rper gegen Tumor-Nekrose-Faktor alpha (TNF alpha) werden zunehmend bei schwer verlaufenden chronisch-entz\u00fcndlichen Erkrankungen angewendet (1). A.J.K. Ostor et al. aus England (2) berichten \u00fcber Verl\u00e4ufe bei drei Patienten mit Rheumatoider Arthritis (RA), deren pr\u00e4existente pulmonale Manifestation (Fibrosierende Alveolitis) nach Einsatz von Infliximab (Remicade\u00ae) mit Todesfolge exazerbierte. Die Patienten (zwei Frauen, ein Mann) waren zwischen 67 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1265,1266,1267,1263,1262,1257,1260,1261,1259,1258,1264],"class_list":["post-575","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alveolitis","tag-fibrosierende-alveolitis","tag-infliximab","tag-tnf-alpha-antagonisten","tag-tnf-alpha-antikoerper","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-antikoerper","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=575"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/575\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}